| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
1,770,000,000 |
| Market
Cap: |
298.37(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$132.51 - $182.1 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 560 |
| Guru Rank Value : 3 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile AbbVie is a research-based biopharmaceutical company. Co. operates as a single business segment dedicated to the research and development, manufacturing, commercialization and sale of medicines and therapies. Co.'s products include: immunology products such as Humira, Skyrizi, and Rinvoq; oncology products such as Imbruvica and Venclexta/Venclyxto; aesthetics products such as Botox Cosmetic and Juvederm Collection; neuroscience products such as Botox Therapeutic, Vraylar, and Ubrelvy; eyecare products such as Lumigan/Ganfort, Alphagan/Combigan, and Restasis; women's health products such as Lo Loestrin and Orilissa/Oriahnn; and other key products such as Creon, Lupron, and Synthroid.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
80,031 |
461,916 |
540,416 |
831,596 |
| Total Sell Value |
$14,256,265 |
$81,646,316 |
$93,320,391 |
$138,453,569 |
| Total People Sold |
2 |
9 |
9 |
12 |
| Total Sell Transactions |
2 |
11 |
13 |
29 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Roberts Rebecca B |
Director |
– • – |
2021-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,681 |
8,332 |
|
- |
|
| Waddell Frederick H |
Director |
– • – |
2021-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,681 |
23,562 |
|
- |
|
| Liddy Edward M |
Director |
– • – |
2021-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,681 |
26,683 |
|
- |
|
| Tilton Glenn F |
Director |
– • – |
2021-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,681 |
46,168 |
|
- |
|
| Austin Roxanne S |
Director |
– • – |
2021-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,681 |
121,128 |
|
- |
|
| Freyman Thomas C |
Director |
– • – |
2021-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,681 |
121,355 |
|
- |
|
| Burnside William H.l. |
Director |
– • – |
2021-05-07 |
4 |
A |
$0.00 |
$0 |
D/D |
1,681 |
21,562 |
|
- |
|
| Strom Carrie C |
SVP & Pres Global Allerg Aesth |
• – – |
2021-05-03 |
4 |
S |
$112.40 |
$470,282 |
D/D |
(4,184) |
59,225 |
|
7% |
|
| Strom Carrie C |
SVP & Pres Global Allerg Aesth |
• – – |
2021-05-03 |
4 |
OE |
$41.39 |
$173,176 |
D/D |
4,184 |
63,409 |
|
- |
|
| Strom Carrie C |
SVP & Pres Global Allerg Aesth |
• – – |
2021-03-07 |
4 |
D |
$106.70 |
$13,124 |
D/D |
(123) |
59,225 |
|
- |
|
| Strom Carrie C |
SVP & Pres Global Allerg Aesth |
• – – |
2021-03-06 |
4 |
D |
$106.70 |
$37,985 |
D/D |
(356) |
59,348 |
|
- |
|
| Strom Carrie C |
SVP & Pres Global Allerg Aesth |
• – – |
2021-03-05 |
4 |
D |
$105.65 |
$47,331 |
D/D |
(448) |
59,704 |
|
- |
|
| Strom Carrie C |
SVP & Pres Global Allerg Aesth |
• – – |
2021-03-02 |
4 |
D |
$108.41 |
$87,812 |
D/D |
(810) |
60,152 |
|
- |
|
| Gonzalez Richard A |
Chairman of the Board and CEO |
• • – |
2021-03-02 |
4 |
OE |
$54.86 |
$9,332,399 |
D/D |
170,113 |
546,710 |
|
- |
|
| Stewart Jeffrey Ryan |
SVP, US Commercial Operations |
• – – |
2021-03-01 |
4 |
S |
$108.59 |
$1,495,576 |
D/D |
(13,773) |
50,969 |
|
-8% |
|
| Sorg Elaine K. |
SVP, US Commercial Operations |
• – – |
2021-03-01 |
4 |
S |
$108.61 |
$916,642 |
D/D |
(8,440) |
17,595 |
|
-8% |
|
| Richmond Timothy J. |
EVP, Chief HR Officer |
• – – |
2021-03-01 |
4 |
S |
$108.59 |
$2,119,041 |
D/D |
(19,514) |
0 |
|
-8% |
|
| Gonzalez Richard A |
Chairman of the Board and CEO |
• • – |
2021-03-01 |
4 |
S |
$108.61 |
$18,476,204 |
D/D |
(170,113) |
376,597 |
|
-8% |
|
| Stewart Jeffrey Ryan |
SVP, US Commercial Operations |
• – – |
2021-02-28 |
4 |
D |
$107.74 |
$1,180,507 |
D/D |
(10,957) |
64,742 |
|
- |
|
| Sorg Elaine K. |
SVP, US Commercial Operations |
• – – |
2021-02-28 |
4 |
D |
$107.74 |
$723,582 |
D/D |
(6,716) |
26,035 |
|
- |
|
| Gosebruch Henry O |
EVP, Chief Strategy Officer |
• – – |
2021-02-28 |
4 |
D |
$107.74 |
$2,460,027 |
D/D |
(22,833) |
48,711 |
|
- |
|
| Michael Robert A. |
EVP, Chief Financial Officer |
• – – |
2021-02-28 |
4 |
D |
$107.74 |
$1,509,006 |
D/D |
(14,006) |
37,877 |
|
- |
|
| Hudson Thomas J |
SVP, R&D and CSO |
• – – |
2021-02-28 |
4 |
D |
$107.74 |
$833,908 |
D/D |
(7,740) |
29,372 |
|
- |
|
| Severino Michael |
Vice Chairman |
• – – |
2021-02-28 |
4 |
D |
$107.74 |
$3,132,756 |
D/D |
(29,077) |
103,835 |
|
- |
|
| Richmond Timothy J. |
EVP, Chief HR Officer |
• – – |
2021-02-28 |
4 |
D |
$107.74 |
$1,672,556 |
D/D |
(15,524) |
19,514 |
|
- |
|
765 Records found
|
|
Page 10 of 31 |
|
|
3.13 (1.89%) 
